HB5850 - To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
US Congress - 118th Congress
Introduced byTracey Mann, John R. Moolenaar
Last updated 12 months ago
2 Co-Sponsors
STATUS
Introduced
Verifications Required
You must be a verified voter to do that.
No Thanks, I'll do it later
Verify your identity now